Curis, Inc.
Phosphoinositide 3-kinase inhibitors with a zinc binding moiety

Last updated:

Abstract:

The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.

Status:
Grant
Type:

Utility

Filling date:

29 May 2019

Issue date:

9 Jun 2020